Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model

American Journal of Obstetrics and Gynecology

Volumn 198, Issue 4, 2008, Pages 433.e1-433.e2

  Ceccaldi, Pierre Francois ^a   Ferreira, Claudia ^a   Gavard, Laurent ^a   Gil, Sophie ^b   Peytavin, Gilles ^c   Mandelbrot, Laurent ^a  

^a HÔPITAL LOUIS MOURIER   (France)

^b Department of Economic and Social Sciences   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

antiretrovirals; enfuvirtide; ex vivo perfused human cotyledon; HIV and pregnancy; placental transfer

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE; PHENAZONE;

ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; EX VIVO STUDY; FEMALE; FETUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR WEIGHT; PLACENTA PERFUSION; PLACENTAL TRANSFER; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; VALIDATION PROCESS; VENOUS BLOOD;

EID: 41349120911     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.10.802     Document Type: Article

References (12)

1. Williams I.G. Enfuvirtide (Fuzeon): the first fusion inhibitor. Int J Clin Pract 57 (2003) 890-897
2. Lalezari J.P., DeJesus E., Northfelt D.W., et al. A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 8 (2003) 279-287
3. McKinney Jr. R.E., and Cunningham C.K. Newer treatments for HIV in children. Curr Opin Pediatr 16 (2004) 76-79
4. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1 Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. Accessed Oct. 12 (2006). http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf
5. Patrick Y. French experts group's recommendations for medical management of HIV infection, highlights and recommendations (2006). http://www.sante.gouv.fr/htm/dossiers/sida/rapportexperts2006_anglais.pdf
6. Wensing A.M., Boucher C.A., van Kasteren M., van Dijken P.J., Geelen S.P., and Juttmann J.R. Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir. AIDS 20 (2006) 1465-1467
7. Meyohas M.C., Lacombe K., Carbonne B., Morand-Joubert L., and Girard P.M. Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough. AIDS 18 (2004) 1966-1968
8. Brennan-Benson P., Pakianathan M., Rice P., et al. Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta. AIDS 20 (2006) 297-299
9. Cohan D., Feakins C., Wara D., et al. Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. AIDS 19 (2005) 989-990
10. Schneider H., and Huch A. Dual in vitro perfusion of an isolated lobe of human placenta: Method and instrumentation. Contrib Gynecol Obstet 13 (1985) 40-47
11. Gavard L., Gil S., Peytavin G., et al. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am J Obstet Gynecol 195 (2006) 296-301
12. Ghosn J., Chaix M.L., Peytavin G., et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 18 (2004) 1958-1961